top of page
For most cost-effective consulting services:
Click here
Home
All News
Pharma
APAC
Brazil
Canada Pharma
China Pharma
Europe Pharma
India Pharma
Japan Pharma
North America
Saudi Arabia
US FDA Approvals
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
Germany Healthcare
Italy
United Kingdom Healthcare
APAC - Healthcare News
Brazil Healthcare
Healthcare Policies
Conferences
About
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
US_PayerNews
Radioligand therapy
NICE recommendations
Germany Healthcare Pharma News
HAS Assessment Outcomes
Neurology
Immunology
Blood Disorders
Oncology
Kidney Diseases
Cardiovascular Diseases
Infectious_Vaccines
Search
From $31.60 to $25: How New PBS Rules Make Prescriptions More Affordable
Badari Andukuri
Feb 5
PBS Adds Zytorvi, First Funded Immunotherapy Option for Australians with Recurrent or Metastatic Nasopharyngeal Carcinoma | iPharmaCenter
Badari Andukuri
Dec 5, 2025
NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter
Badari Andukuri
Dec 2, 2025
Australia Healthcare News | Drug reimbursement
ipharmaservices
Jan 31, 2022
Australia Drug Approvals | Drugs approved by TGA
Badari Andukuri
Jan 28, 2022
PBAC News Updates
ipharmaservices
Nov 21, 2021
TGA Approved Zolgensma | TGA Drug approvals
ipharmaservices
Mar 10, 2021
AUSTRALIA HEALTHCARE SYSTEM
ipharmaservices
Feb 9, 2019
bottom of page
